Kezar Life Sciences declared a dividend of rights to purchase preferred stock and adopted a rights plan to protect against a potential takeover by Concentra Biosciences, which proposed to acquire the company for $1.10 per share; the company has approximately $148 million in cash and marketable securities as of September 30, 2024.